美股异动｜AI药物开发商Absci一度涨超21%，与甲骨文和AMD达成合作

Core Viewpoint - Absci, an artificial intelligence drug developer, experienced a significant stock increase of over 21%, reaching a peak of $2.89, following the announcement of a collaboration with Oracle and AMD to enhance AI-driven drug discovery processes [1] Company Summary - Absci announced a partnership with Oracle and AMD to accelerate its generative AI-driven drug discovery platform [1] - The collaboration will leverage Oracle's AI infrastructure and AMD's latest hardware to improve the drug discovery process [1]